Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Sales: 2020-2025

Historic Return on Sales for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to -13.93%.

  • Insight Molecular Diagnostics' Return on Sales rose 4736.00% to -13.93% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.93%, marking a year-over-year increase of 4736.00%. This contributed to the annual value of -32.45% for FY2024, which is 3050.00% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Sales stood at -13.93% for Q3 2025, which was up 7.03% from -14.98% recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Sales peaked at -7.46% during Q2 2021, and registered a low of -61.29% during Q3 2024.
  • Moreover, its 3-year median value for Return on Sales was -32.38% (2024), whereas its average is -33.11%.
  • In the last 5 years, Insight Molecular Diagnostics' Return on Sales tumbled by 4,826bps in 2023 and then spiked by 4,736bps in 2025.
  • Insight Molecular Diagnostics' Return on Sales (Quarterly) stood at -8.73% in 2021, then crashed by 2,006bps to -28.79% in 2022, then skyrocketed by 622bps to -22.57% in 2023, then crashed by 981bps to -32.38% in 2024, then soared by 4,736bps to -13.93% in 2025.
  • Its last three reported values are -13.93% in Q3 2025, -14.98% for Q2 2025, and -15.24% during Q1 2025.